Slides
Page 1
Presentation Materials - Our Growth Strategy - September 1, 2026
Page 2
111Key Messages / Contents Today I'd like to focus on three key messages: ⚫ Strong business momentum ⚫ Sustainable growth drivers ⚫ Clear path to shareholder value creation Key Messages Contents • Investment Highlights • Key Growth Driver • Growth Strategy - New Medium Term Management Plan • Capital Strategy • Forecast for FY2026
Page 3
2 Investment Highlights
Page 4
333 8,224 10,275 11,868 13,684 14,635 17,400 3,375 4,615 5,715 7,031 7,156 8,650 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 0 5,000 10,000 15,000 20,000 FY2021* FY2022* FY2023 FY2024 FY2025 FY2026 Forecast Net sales Operating income (Millions of yen) Investment Highlights Global Niche Leadership Global Niche Top Share Products World No. 1 DAP Resin Epichlorohydrin Rubber Allyl Ethers Pharmaceutical Purification Materials (Silica gel for liquid chromatography) Healthcare-driven Growth Healthcare segment revenue doubled in 5 years Improving profitability 88,084 104,208 94,557 96,434 99,961 108,000 12,401 15,557 10,492 13,246 17,634 20,500 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 0 20,000 40,000 60,000 80,000 100,000 120,000 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026 Forecast 14.1% 14.9% 11.1% 13.7% 17.6% 19.0% Net sales (Millions of yen) Operating income (Millions of yen) ■ Net sales ■ Operating income ● Operating profit margin Operating profit margin reached 17.6%, maintaining a top-level of profitability in the chemical industry in Japan Investment Highlights
Page 5
444 Investment Highlights Diversified Business Portfolio with Healthcare as a Key Growth Driver *Exclude common expenses 41,741 42% 27,935 28% 14,635 14% 15,649 16% 6,194 33% 4,634 24% 7,156 38% 946 5% Net sales 99,961 (Million yen) Operating income 17,634* (Million yen) ■ Basic Chemicals ■ Healthcare ■ Functional Chemicals ■ Trading and others Segment Role in Portfolio Main Products Basic Chemicals Stable cash generator Chlor-alkali products, Epichlorohydrin(EP), Allyl Chloride(AC), etc. Functional Chemicals Global niche leader Allyl Ethers, Epichlorohydrin Rubber, Acrylic Rubber, Diallyl Phthalates（DAP） Resin, etc. Healthcare Growth and profit driver Pharmaceutical Purification Materials, Analytical Equipment, Packed Columns, APIs and their intermediates, etc. Trading & Others Customer access platform Sales and Transportation and Storage of Chemical Products, Consumer products, Building Materials, Materials Recycling, etc. Sales by Region(%) Net sales: 99,961 Million yen Japan Asia Europe Others 61% 27% 8% 4% Financial Results FY2025
Page 6
5 Key Growth Driver - Our Strength and Growth Background of Silica gel -
Page 7
666 Food desiccants Particle size: - 1mm Market price (per kg) : several hundred yen What is Osaka Soda’s Silica gel? ⚫ Osaka Soda's silica gel is used for pharmaceutical refining and is different from food desiccants and cosmetic ingredients. ⚫ Its fine particle size of 50 μm or less requires advanced manufacturing technologies, making it a high-value-added product. Cosmetic ingredients Particle size: - tens of μm Market price (per kg) : several thousand yen Separation and purification of pharmaceuticals Particle size: 50 μm or less Market price (per kg) : Tens of thousands - several millions of yen Silica gel applications Low added value High added value Key Growth Driver
Page 8
777 What are Our Strength? No.1 Market Share, Largest Production Capacity Advanced Technology and Quality Addressing Long-term Demand Growth Leading Position High Entry Barrier Structural Demand Growth ⚫ Holding over 70% market share in silica gel for pharmaceutical purification material. ⚫ Proprietary manufacturing technologies in particle size control, pore size control, and surface modification. ⚫ Customers can choose the optimal separation material for over 300 grades ⚫ Silica gel manufactured under strict quality control is essential for the analysis and purification of pharmaceuticals. Other companies Osaka Soda 70%+ ⚫ Expansion in diabetes and obesity treatment markets driving 15 – 20% annual growth. ⚫ Developing and commercializing ultra-high surface area silica gels and ADME gels to capture demand from biopharmaceuticals and future purification applications Key Growth Driver
Page 9
888 (Fiscal Year) （Capacity : times） Silica Gel Demand Trends and Manufacturing Capacity ⚫ Based on the manufacturing capacity expanded under the previous medium-term management plan, plan to double healthcare segment earnings by the final year of the new medium-term management plan ⚫ In FY2028, demand is expected to exceed current capacity, so manufacturing capacity will be further expanded to approximately double ⚫ Market remains active despite risks of delays, supported by emerging market expansion and new drug launches in the US and Europe 0 1 2 3 4 5 6 7 8 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Manufacturing capacity Capacity expansion Operation response Demand Forecast (Latest) Demand forecast range Key Growth Driver
Page 10
9 Growth Strategy New Medium-Term Management Plan - Transform Our Future 2030 -
Page 11
101010 Management Targets (Unit : Billions of yen) FY2025 Results FY2028 Target FY2030 Target Growth Rate (FY2025 vs. FY2030) Net sales 100.0 120.0 130.0 ＋30.0% Operating income 17.6 22.0 30.0 ＋70.5% EBITDA＊ 22.0 30.0 39.0 ＋77.3% ROE 12.7% 13.0% or higher 15.0% or higher ー Total payout ratio 61.3% 70.0% or higher 70.0% or higher ー ＊ EBITDA : Operating income + Depreciation expenses Assumptions (not taking into account the situation in the Middle East) Exchange rate USD/JPY 145 EUR/JPY 170 Naphtha price 63,000 Yen/kL １. Rebuilding the Value of Existing Businesses and Accelerating Growth in Healthcare ２. Creating New Businesses by Mobilizing Companywide Capabilities ３. Strengthening the Management Foundation to Adapt to Changes in the Business Environment Basic Policy New Medium-Term Management Plan, Transform Our Future 2030 ／ Growth Strategy
Page 12
111111 Forecast by Segment (Unit：Millions of yen) Basic Chemicals Net sales 41,741 44,500 45,000 ＋7.8% Operating income 6,194 4,600 5,600 (9.6%) Operating margin 14.8% 10.3% 12.4% ― Functional Chemicals Net sales 27,935 35,000 40,000 ＋43.2% Operating income 4,634 5,700 7,800 ＋68.3% Operating margin 16.6% 16.3% 19.5% ― Healthcare Net sales 14,635 24,000 28,500 ＋94.7% Operating income 7,156 12,400 16,900 ＋136.2% Operating margin 48.9% 51.7% 59.3% ― Trading and Others Net sales 15,649 16,500 16,500 ＋5.4% Operating income 946 950 1,100 ＋16.3% Operating margin 6.0% 5.8% 6.7% ― Company-wide, eliminations Operating income (1,297) (1,650) (1,400) ― FY2025 FY2028 FY2030 Growth Rate Results Target Target FY2025 vs. FY2030 Total Net sales 99,961 120,000 130,000 ＋30.1% Operating income 17,634 22,000 30,000 ＋70.1% Operating margin 17.6% 18.2% 23.1% ― Assumptions Exchange rate： USD/JPY 145, EUR/JPY 170 Naphtha price： 63,000 Yen/kL New Medium-Term Management Plan, Transform Our Future 2030 ／ Growth Strategy
Page 13
12 Basic Policy 1 Rebuilding the Value of Existing Businesses and Accelerating Growth in Healthcare Accelerate growth in healthcare while rebuilding the value of existing businesses and strengthening competitiveness
Page 14
131313 41,741 44,500 45,000 6,194 4,600 5,600 0 5,000 10,000 15,000 20,000 25,000 30,000 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 50,000 2025 2028 2030 14.8% 10.3% 12.4% Strategy 24％ Resilience and Cost Reduction 76% Investment Plan Approx. ¥37.0 billion Main Products Net Sales Variance (25 vs. 30) Chlor-alkali +3.0 Epichlorohydrin (0.8) New Business +1.0 Net sales (Millions of yen) Operating income (Millions of yen) ■Net sales ■Operating income ●Operating margin Basic Chemicals ⚫ Deepen electrolysis and AC/EP chains, and promote investments in strengthening the business and reducing costs for sustainable growth ⚫ Stabilize the sales base by deepening our presence in the domestic market and expanding exports ⚫ Chlor-alkali : Declining domestic demand due to petrochemical industry restructuring in Japan ⚫ Epichlorohydrin : Increase in by-product glycerin is limited and expected to remain within a competitive range ⚫ New Business : Die-bonding materials for power semiconductors are expected to grow at 5 – 10% annually Business EnvironmentSegment Targets (Fiscal Year) ⚫ Promote community-based sales (Chlor-alkali) ⚫ Capture new chlorine demand ⚫ Strengthen flexible sales systems (Epichlorohydrin) ⚫ Reduce costs through improved production efficiency in existing businesses ⚫ Commercialization of silver nanoparticles Key Measures Policy (Billions of yen) New Medium-Term Management Plan, Transform Our Future 2030 ／Basic Policy 1
Page 15
141414 27,935 35,000 40,000 4,634 5,700 7,800 0 5,000 10,000 15,000 20,000 25,000 30,000 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 50,000 2025 2028 2030 16.6% 16.3% 19.5% Strategy 67％ Resilience and Cost Reduction 33% Investment Plan Approx. ¥7.5 billion Main Products Net Sales Variance (25 vs. 30) Synthetic Rubbers / Synthetic Resins +3.9 Allyl Ethers +4.6 Electrodes +1.4 New Business +1.3 etc. +0.8 Net sales (Millions of yen) Operating income (Millions of yen) ■Net sales ■Operating income ●Operating margin Functional Chemicals ⚫ Maximize profitability by expanding the market share of existing products and cost reductions ⚫ Work to create the next Global Niche Top products ⚫ Synthetic Rubbers : Declining ICE vehicle numbers, but increasing substitution demand from other materials ⚫ Synthetic Resins : Continued growth in demand for UV offset inks in China ⚫ Allyl Ethers : Stable growth of 3 – 4% annually ⚫ Next-generation Storage Battery Materials : Full-scale commercialization of all-solid-state batteries is expected after 2030 Business EnvironmentSegment Targets (Fiscal Year) Policy ⚫ Expand market share and capture substitution demand (Synthetic Rubber and Synthetic Resin) ⚫ Expand into applications for high-voltage and high heat- resistant molding materials (Synthetic Resin) ⚫ Expand capacity (Allyl Ethers) ⚫ Promote improvement in unit consumption, yield enhancement, and process automation ⚫ Commercialization and business development of next- generation storage battery materials Key Measures (Billions of yen) New Medium-Term Management Plan, Transform Our Future 2030 ／Basic Policy 1
Page 16
151515 * Pharmaceutical purification materials(Silica gel), analytical equipment, packed columns Main Products Net Sales Variance (25 vs. 30) Chromatography* +12.6 APIs and their Intermediates +1.2 Strategy 94％ Resilience and Cost Reduction 6% Investment Plan Approx. ¥17.0 billion Healthcare ⚫ For pharmaceutical purification materials, maintain and expand our top global market share by strategically expanding manufacturing capacity early in anticipation of market expansion ⚫ Enter the polymer gel market to build a new business foundation in growth areas such as nucleic acid and peptide pharmaceuticals ⚫ For active pharmaceutical ingredients (APIs) and their intermediates, expand our portfolio by increasing manufacturing capacity and making a full-scale entry into the biopharmaceutical business Business EnvironmentSegment Targets Policy ⚫ Expand silica gel production facilities ⚫ Productivity improvement through yield improvement ⚫ Expand sales in Europe, the U.S., and emerging markets ⚫ Expand polymer gel lineup through collaboration with Mitsubishi Chemical ⚫ Expand APIs production facilities ⚫ Accelerate commercialization of VHH antibodies Key Measures 14,635 24,000 28,500 7,156 12,400 16,900 0 5,000 10,000 15,000 20,000 25,000 30,000 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 50,000 2025 2028 2030 48.9% 51.7% 59.3% Net sales (Millions of yen) Operating income (Millions of yen) ■Net sales ■Operating income ●Operating margin (Fiscal Year) ⚫ Pharmaceutical purification silica gel Expansion in diabetes and obesity treatment markets driving 15 – 20% annual growth ⚫ APIs and their Intermediates Small-molecule drugs grow at 3 – 5% annually Peptide, nucleic acid, and antibody pharmaceuticals expected to grow at around 10% annually (Billions of yen) New Medium-Term Management Plan, Transform Our Future 2030 ／Basic Policy 1
Page 17
161616 15,649 16,500 16,500 946 950 1,100 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 0 5,000 10,000 15,000 20,000 25,000 2025 2028 2030 6.0% 5.8% 6.7% Main Products Net Sales Variance (25 vs. 30) Consumer products +1.5 Functional products (0.6) etc. (0.9) Trading and Others Net sales (Millions of yen) Operating income (Millions of yen) ■Net sales ■Operating income ●Operating margin ⚫ Enhancing the Group’s information-gathering capabilities as a trading company and pursuing new business opportunities ⚫ Maintaining and improving profitability by reviewing the business portfolio Segment Targets (Fiscal Year) Policy ⚫ Consumer products Steady growth of the portable battery market is expected ⚫ Building Materials The renovation market remains solid ⚫ Functional products Printing-related products are on a shrinking trend Business Environment ⚫ Strengthen development of proprietary consumer products(Including semi- solid-state batteries) ⚫ Develop new applications and markets for existing products ⚫ Expand handling of environmentally friendly products ⚫ Stabilizing profitability through business models for photosensitive resin and technical services Key Measures (Billions of yen) New Medium-Term Management Plan, Transform Our Future 2030 ／Basic Policy 1
Page 18
17 Basic Policy 2 Creating New Businesses by Mobilizing Companywide Capabilities Drive the creation of new products by leveraging proprietary technologies, with a focus on electronic and life science materials
Page 19
181818 Previous MTP FY2026 FY2027 FY2028 FY2029 FY2030 High-ionic-conductivity materials for all-solid-state batteries ◎ ● Polymer electrolytes for LIB ◎ ● Polymer for semi-solid-state batteries ◎ ● Carbon nanotubes ◎ Silver nanoparticles ◎ ● Dielectric elastomers ◎ ● High-voltage, heat-resistant resins for molding materials ◎ ● Lactic acid bacterium OS-1010 ◎● Polymer for cosmetics ◎ ● VHH antibodies ◎ ● New purification materials ◎● ◎ ◎ Commercialization ● ● Mass production FY030 Target Sales (billions of yen) Electronic Materials 3.0 Life Science Materials 2.0 Pilot plant construction Acquisition of “Foods with Function Claims” certification Develop into a new pillar of earnings FY2035 Pilot production Pilot production ⚫ New product development in growth areas： Promoting the development of new products leveraging proprietary technologies, focusing on electronic materials and life science materials where growth is expected ⚫ Strengthening Theme Exploration Capabilities： Strategic utilization of the knowledge, expertise, networks and other resources of corporate divisions throughout the company Policy New Medium-Term Management Plan, Transform Our Future 2030 ／Basic Policy 2
Page 20
19 Basic Policy 3 Strengthening the Management Foundation to Adapt to Changes in the Business Environment Build an organization that balances efficiency and adaptability, and advance sustainability management
Page 21
202020 Improve managerial skills, raise the level of organizational capabilities, and build a human resource management foundation with the aim of becoming a company where employees can fully demonstrate their abilities Promote innovation and transformation in production technology (including the handling down of skills and techniques), and R&D (theme searches, MI, etc.), and improve operational efficiency on a company-wide scale through the use of AI and data Strengthen facility management and autonomous maintenance while enhancing operational management in order to prevent occupational accidents, incidents, and production problems and avoid recurrence Further strengthen the risk management system in light of the diversification of major company-wide risks associated with the expansion of the company’s size Human Resource Strategy Risk Management DX Promotion Safe and Stable Production New Medium-Term Management Plan, Transform Our Future 2030 ／Basic Policy 3
Page 22
212121 GHG emissions reduction roadmap (total Scope 1 and 2) 533 475 277 497 40 △ 130 △ 35 373 75 △ 174 △ 49 △ 26 △ 126 △ 73 0 2013 (基準年) 2022 2023 2024 2030 (目標) 2050 （目標） 0 100 200 300 400 500 600 （thousand t-CO2e） Increased production Carbon neutrality Effect of changes in the emission factor for electricity Energy efficiency improvements Fuel conversion Introduction of green electricity Offsets (CCUS, credits) Effect of changes in the emission factor for electricity Energy efficiency improvements 30% Reduction ⚫ Aim to reduce GHG emissions (Scope 1 and 2) by 30% from FY2013 levels by FY2030 ⚫ Enhance energy efficiency through process optimization, introduction of high-efficiency equipment, and heat recovery ⚫ Establish an electricity retail company to reduce GHG emissions through diversification of power sources, including renewable energy Carbon Neutrality Policy Promote efforts such as improving energy efficiency, promoting the use of bio-derived raw materials, introducing non-fossil fuel electric power, carrying out studies on the use of recycled fuels, etc. in order to achieve carbon neutrality by FY2050 Increased production (base year) (Target) (Target) (Fiscal Year) New Medium-Term Management Plan, Transform Our Future 2030 ／Basic Policy 3
Page 23
22 Capital Strategy Capital allocation and shareholder returns aimed at enhancing corporate value
Page 24
232323 Cash Allocation for Future Growth (FY2026 – FY2030) ⚫ Shortfall in cash on hand will be temporarily covered by short- term debt financing ⚫ Healthcare-related: Approx. 16 billion yen ⚫ Basic chemicals-related: Approx. 28 billion yen ⚫ Total payout ratio of 70% or more Total 127 billion yen Capital Expenditures Approx. 67 billion yen Shareholder Return Approx. 60 billion yen Investment and Financing Approx. 20 billion yen or more Cash flows from operating activities Approx.110 billion yen Cash on Hand etc. M&As and alliances Strategic Investments Approx. 32 billion yen Resilience and cost reduction investments Approx. 35 billion yen Dividends and share buybacks ⚫ Operating cash flow is expected to reach 110 billion yen cumulatively over five years, driven by significant growth in the healthcare segment ⚫ Generated cash and available funds will be used for strategic investments as well as Resilience and cost reduction investments, while enhancing shareholder returns Cash Allocation Capital Strategy
Page 25
242424 Capital Expenditures Approx. 67 billion yen Strategic Investments Approx. 32 billion yen Healthcare Approx. 16 billion yen ⚫ Expansion of silica gel production facilities (over 10 billion yen) ⚫ Capacity expansion of APIs and intermediates ⚫ Scale-up of biopharmaceutical manufacturing facilities, etc. Functional Chemicals Approx. 5 billion yen ⚫ Pilot plant for all-solid-state battery materials ⚫ Capacity expansion of allyl ethers ⚫ Capacity expansion of acrylic rubber, etc. R&D and Others Approx. 2 billion yen Capital Expenditures Plan Resilience and Cost Reduction Investments Approx. 35 billion yen Resilience Investments Approx. 32.5 billion yen ⚫ Upgrading of electrolysis facilities (Mizushima, Okayama, etc.) ⚫ Equipment replacement through improvement maintenance Cost Reduction Investments Approx. 2.5 billion yen ⚫ Improvement in unit consumption and yield ⚫ Steam recovery, etc. (environmental impact reduction) Basic Chemicals: Approx. 9 billion yen ⚫ Bio-propylene facilities ⚫ Mass production facilities for silver nanoparticles, etc. ⚫ Strategic investments : focused on Healthcare to accelerate growth ⚫ Resilience and cost reduction investments : Maintain safe and stable operations and further reinforce its position as a cash cow, mainly in Basic Chemicals Capital Strategy
Page 26
252525 1.5 2.5 1.9 4.5 3.1 4.2 9.5 0 2 4 6 8 10 12 14 16 2019 2020 2021 2022 2023 2024 2025 2026-2030 Shape the Future-2025BRIGHT-2020 EMPOWER THE NEXT-22 Transform Our Future 2030 (Fiscal Year) Total shareholder returns（ Dividends ＋ Stock buybacks） (billion yen) Shareholder Returns ⚫ Target a total payout ratio of 70% or higher, significantly raising it from the previous medium-term management plan target (40% or higher), and strengthen shareholder returns Total payout ratio 23.7% 41.6% 19.8% 43.0% 40.4% 40.7% 61.3% 70% or higher（Target） Capital Strategy
Page 27
26 Forecast for FY2026
Page 28
272727 FY2026 Initial Forecast FY2026 Revised Forecast Change (YoY) (Millions of yen) To sales To sales Amount Percentage Net sales 106,000 – 108,000 – 2,000 1.9% Operating income 19,000 17.9% 20,500 19.0% 1,500 7.9% Ordinary income 20,400 19.2% 22,100 20.5% 1,700 8.3% Net income 13,600 12.8% 14,800 13.7% 1,200 8.8% Earnings per share 110.70 yen – 121.74 yen – – – Assumptions* FY2026 Initial Forecast FY2026 Revised Forecast※ Yen / USD 145 yen 160 yen Yen / Euro 170 yen 184 yen Naphtha price (Yen / kL) 63,000 yen 99,500 yen Forecast for FY2026 Forecast for FY2026 ⚫ Reflecting profit growth driven by continued expansion in the Healthcare business, both operating income and ordinary income are expected to reach record highs ⚫ The basic policy is to revise product prices in a timely manner in response to rising fuel and raw material prices, and the impact of the Middle East situation on the Company’s business is expected to remain limited *Not taking into account the situation in the Middle East ※Applied only to the second-quarter forecast; assumptions for the second half remain unchanged from the initial forecast.
Page 29
282828 FY2025 FY2026 Revised Forecast Change (YoY) (Millions of yen) 1H 2H Full Year 1H 2H Full Year 1H 2H Full Year Net sales Basic Chemicals 20,302 21,439 41,741 22,000 21,100 43,100 1,698 (339) 1,359 Functional Chemicals 13,596 14,339 27,935 15,700 15,700 31,400 2,104 1,361 3,465 Healthcare 6,709 7,926 14,635 8,300 9,100 17,400 1,591 1,174 2,765 Trading & Others 8,223 7,426 15,649 8,000 8,100 16,100 (223) 674 451 Total 48,832 51,129 99,961 54,000 54,000 108,000 5,168 2,871 8,039 Operating income Basic Chemicals 2,946 3,248 6,194 2,900 2,900 5,800 (46) (348) (394) Functional Chemicals 1,926 2,708 4,634 3,400 2,950 6,350 1,474 242 1,716 Healthcare 3,447 3,709 7,156 3,900 4,750 8,650 453 1,041 1,494 Trading & Others 462 484 946 700 400 1,100 238 (84) 154 Company-wide, eliminations (671) (626) (1,297) (600) (800) (1,400) 71 (129) (103) Total 8,111 9,523 17,634 10,300 10,200 20,500 2,189 677 2,866 Forecast for FY2026 FY2026 Revised Forecast by Segment ⚫ Raised 1H forecasts for both net sales and profits, reflecting higher Allyl Ethers market prices partly due to the situation in the Middle East, a weaker-than-assumed yen, and firm sales of healthcare products ⚫ Basic Chemicals: Reflecting fluctuations in epichlorohydrin market conditions and rising electricity and raw material costs ⚫ Functional Chemicals: Allyl ethers are expected to maintain their market recovery ⚫ Healthcare: Demand for pharmaceutical purification materials is expected to continue expanding, reflecting the effects of increased production capacity at both the Matsuyama and Amagasaki plants
Page 30
292929 13 13 16 18 18 19 28 30 23.7 41.6 19.8 43.0 40.4 40.7 61.3 0 20 40 60 80 100 0 5 10 15 20 25 30 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026 (Plan) Dividend increase (left scale) Annual dividend per share (left scale) Total payout ratio (right scale) （％） Share buyback (Billion Yen) – 1.0 – 2.2 0.8 1.8 6.0 Shareholder Returns ⚫ Targeting a total payout ratio of 70% or higher under the new medium-term management plan ⚫ To further enhance shareholder returns, a share buyback program of up to ¥5.0 billion is underway through September 30, 2026 ⚫ Following the upward revision of our earnings forecast, we raised the annual dividend forecast by ¥2 per share to ¥30 per share * Figures for dividend per share are converted after the stock split.(effective October 1, 2024) (Yen) Forecast for FY2026 Increased dividend
Page 31
Contact : Osaka Soda Co., LTD. Public Relations Group, Corporate Planning Department TEL : +81-(0)6-7733-1005 This document is not prepared for the purpose of soliciting investment in securities issued by us. All information contained in this document represents our views as of the time of preparation of this document. Please note that we do not guarantee or promise accuracy and completeness.